---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455557"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2026-11-10T21:27:44+00:00"
generated_at: "2026-11-10T21:29:12.038233+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biomea Q3 net loss narrows to $6.2M; cash of $26.8M funds runway into Q2 2027

## Summary
- Net loss attributable to common stockholders $6.2M vs $16.4M in Q3 2025; nine-month net loss $26.9M vs $66.4M.
- R&D expense $8.5M, down $5.9M YoY on lower manufacturing, clinical and headcount costs; G&A $4.4M vs $4.2M.
- Cash, cash equivalents and restricted cash $26.8M at Sept 30, 2026; runway projected into Q2 2027.
- COVALENT-211 Phase II enrollment complete in insulin-deficient T2D; Week 26 HbA1c topline data expected Q1 2027. COVALENT-212 topline expected Q2 2027.
- BMF-650 Phase I: 6.1% (6.2 kg) mean weight loss at Day 29 in Cohort 5; 1.5-3.2% in Cohorts 1-4 vs 0.1% placebo; all TEAEs mild or moderate.

## SEC filing metadata
- accession: 0001193125-26-455557
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2026-11-10T21:27:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/0001193125-26-455557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/bmea-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455557
- JSON: https://secwatch.observer/filing/0001193125-26-455557.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.